BioSpace News Archive

PathAI, a global leader in AI-powered pathology, and GlaxoSmithKline (GSK), today announced a strategic multi-year partnership to accelerate scientific research and drug development programs in oncology and non-alcoholic steatohepatitis (NASH) by leveraging PathAI’s technologies in digital pathology including the use of PathAI’s AIM-NASH tool.

NanoVibronix, Inc. today announced that it has received the publication of Guidance from the National Institute for Health and Care Excellence (NICE) with recommendations of the company’s UroShield device.

Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar on April 14th.

Ra Medical Systems, Inc. announces the United States Patent and Trademark Office has granted the company a patent for liquid-filled laser ablation catheters with expanded distal optical windows.

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Pravin Chaturvedi, PhD, a pharmaceutical veteran and leading clinical development expert, has been appointed Chief Scientific Officer (CSO) and Chair of the Scientific Advisory Board (SAB) of Jaguar.

NEOGEN Corporation announced that its Genetic Veterinary Sciences, Inc. facility has received ISO/IEC 17025:2017 accreditation from the American Association for Laboratory Accreditation — the highest recognized quality standard in the world for testing and calibration laboratories.

Evotec SE will announce its financial results for 2021 on Tuesday, 12 April 2022.

Advanced Dermatology and Cosmetic Surgery announces Maragh Dermatology, Surgery and Vein Institute, has joined its brand family of over 150 offices nationwide.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Michael MacLean, currently the chief financial officer, has expanded his role to include responsibilities as chief business officer.

Dialectic Therapeutics, Inc. (Dialectic®), a Texas-based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to DT2216 for adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).